Donald Notman

Direttore Finanziario/CFO presso OCULAR THERAPEUTIX, INC.

Patrimonio netto: 328 289 $ in data 30/04/2024

64 anni

35 relazioni

Health Technology

Consumer Services

Finance

Relazioni attive

Nome	Sesso	Età	Società collegate	Collaborazione
Jeffrey S. Heier	M	63	OCULAR THERAPEUTIX, INC.	9 anni
Charles Warden	M	55	OCULAR THERAPEUTIX, INC.	16 anni
Scott Corning	M	-	OCULAR THERAPEUTIX, INC.	14 anni
Richard Lindstrom	M	76	OCULAR THERAPEUTIX, INC.	12 anni
Merilee Raines	F	68	OCULAR THERAPEUTIX, INC.	3 anni
Leslie Williams	F	64	OCULAR THERAPEUTIX, INC.	5 anni
Seung Suh Hong	M	66	OCULAR THERAPEUTIX, INC.	5 anni
Adrienne Graves	M	69	OCULAR THERAPEUTIX, INC.	1 anni
Karen-Leigh Edwards	M	-	OCULAR THERAPEUTIX, INC.	3 anni
Tracy Smith	F	-	OCULAR THERAPEUTIX, INC.	4 anni
Pravin Dugel	M	60	OCULAR THERAPEUTIX, INC.	-
Philip Strassburger	M	64	OCULAR THERAPEUTIX, INC.	4 anni
Peter K. Kaiser	M	-	OCULAR THERAPEUTIX, INC.	-
Pauline Jen Ryan	F	-	OCULAR THERAPEUTIX, INC.	-
Christopher White	M	62	OCULAR THERAPEUTIX, INC.	5 anni
Peter Jarrett	M	-	OCULAR THERAPEUTIX, INC.	17 anni
Sanjay Nayak	M	54	OCULAR THERAPEUTIX, INC.	-

Mostra altro

Grafico relazionale

Relazione in diverse aziende

Relazioni precedenti

Nome	Sesso	Età	Società collegate	Collaborazione
Amarpreet S. Sawhney	M	57	OCULAR THERAPEUTIX, INC.	13 anni
Antony Mattessich	M	57	OCULAR THERAPEUTIX, INC.	7 anni
Jim O'Shea	M	74	OCULAR THERAPEUTIX, INC.	4 anni
Bruce Peacock	M	72	OCULAR THERAPEUTIX, INC.	8 anni
Joseph Zakrzewski	M	60	Thrasos Therapeutics, Inc. Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada.	-
George Migausky	M	69	OCULAR THERAPEUTIX, INC.	-
Kevin Hanley	M	62	OCULAR THERAPEUTIX, INC.	2 anni
Patricia Kitchen	F	46	OCULAR THERAPEUTIX, INC.	2 anni
Chad Brines	M	-	OCULAR THERAPEUTIX, INC.	4 anni
Jonathan M. Sparks	M	-	OCULAR THERAPEUTIX, INC.	-
Nicole Carta	F	-	OCULAR THERAPEUTIX, INC.	-
Naymisha Patel	F	-	OCULAR THERAPEUTIX, INC.	-
Rabia Ozden	M	56	OCULAR THERAPEUTIX, INC.	3 anni
Daniel M. Bollag	M	63	OCULAR THERAPEUTIX, INC.	2 anni
Michael H. Goldstein	M	57	OCULAR THERAPEUTIX, INC.	-
Gaétan Gravel	M	-	Thrasos Therapeutics, Inc. Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada.	-
Jaswinder S. Chadha	M	56	OCULAR THERAPEUTIX, INC.	6 anni
Amar Sawhney	M	-	OCULAR THERAPEUTIX, INC.	2 anni

Statistiche

Paese	Relazioni	% del totale
Stati Uniti	33	94.29%
Canada	2	5.71%

Età delle relazioni

Attive

Scorse

Uomo

Donna

Amministratori

Dirigenti

Provenienza delle relazioni